Hopen Therapeutics

Hopen Therapeutics is a clinical-stage biotechnology company focused on the development of innovative therapies for rare diseases, particularly those involving copper metabolism and metabolic disorders. The company's lead candidate, HP001, is a copper histidinate formulation currently in clinical trials for the treatment of Menkes disease, a rare and fatal genetic disorder. Hopen's pipeline also includes programs targeting Wilson disease and other orphan indications, utilizing a deep understanding of disease mechanisms to create targeted treatments. Headquartered in Suzhou, China, the company is supported by prominent venture capital firms and aims to address high unmet medical needs in the global rare disease community. The firm leverages its specialized R&D platform to accelerate the translation of scientific discoveries into clinical applications for patients with limited treatment options.